ASPET

OCTOBER 20, 2023

Western blotting was utilized for protein expression and epigenetic studies utilized chromatin immunoprecipitation methods. Furthermore, KET restored acetylated histone occupancy at the Bdnf promoter IV and induced BDNF protein expression in DFP rats. mg/kg s.c., At 6-m following DFP exposure, KET (10 mg/kg, i.p.)

Protein Expression 100

Protein Expression Clinical Trials Therapies FDA 100

ASPET

AUGUST 31, 2023

Proteomic analysis with the use of the Q Exactive HF mass spectrometer, combined with biostatistic tests, performed on UVA-irradiated keratinocytes indicated enhanced and lowered expression of 186 and 160 proteins, respectively.

Protein Expression 100

Protein Expression Treatment 100

Chemical Biology and Drug Design

AUGUST 2, 2023

Group 1: the control group, Group 2: STZ-induced diabetes+insulin treatment group, Group 3: STZ-induced diabetes+linagliptin treatment group, Group 4: STZ-induced diabetes+linagliptin+insulin treatment group, Group 5: STZ-induced diabetes+TUDCA treatment group, Group 6: STZ-induced diabetes+TUDCA+insulin treatment group.

Protein Expression 100

Protein Expression Therapies Treatment Research 100

Chemical Biology and Drug Design

JUNE 8, 2023

Compared with the control group (0 mM SAS), the proliferation of TE-1 cells was significantly inhibited by different concentrations of SAS for different time lengths, and 4 mM SAS treatment for 48 h could obtain the maximum inhibition rate (53.9%).

Protein Expression 100

Protein Expression Treatment Research 100

Chemical Biology and Drug Design

SEPTEMBER 26, 2024

Compound 22 might become a novel antioxidant for the treatment of oxidative stress-related diseases. Western blot and molecular docking indicated that compound 22 may exert antioxidant activity by activating Nrf2 protein expression. As noted in the study, compound 22 has the potential to be a novel antioxidant.

Protein Expression 100

Protein Expression Pharmaceuticals Treatment Disease 100

Chemical Biology and Drug Design

SEPTEMBER 25, 2023

Vinp treatment promotes Wnt proteins to connect the receptors complex on the cell membrane (consisting of FZD and LRP5/6), and then β-catenin is subsequently dissociated from the complex and translocated to the nucleus, activating transcription of downstream target genes. The mechanism diagram of Vinp on PD.

Disease 100

Disease Protein Expression Treatment Research 100

Chemical Biology and Drug Design

SEPTEMBER 24, 2023

This finding provides new ideas for the development of drug targets for the treatment of ischemic stroke. This research is powered to probe whether the molecular mechanism of JAS for IS treatment is coupled with microglia polarization. The polarization of microglia affects IS process.

Regulations 100

Regulations Protein Expression Treatment Research 100

Chemical Biology and Drug Design

AUGUST 9, 2023

A label-free proteomics technology was employed to investigate alterations in protein expression in LoVo cells treated with plumbagin. The LC-MS/MS proteomics assay revealed 78 proteins that were differentially expressed upon treatment with plumbagin.

Bioinformatics 100

Bioinformatics Protein Expression Treatment Research 100

Chemical Biology and Drug Design

AUGUST 23, 2023

The protein expressions were detected via western blot. The THS showed increased inflammation response proteins, mitochondria-dependent apoptosis proteins, and had a compensation effect on the Akt pathway. Ligustrazine at doses of 100 and 1000 μg/mL was administrated in Kupffer cells isolated from THS rats.

Protein Expression 100

Protein Expression Protein Production Treatment Production 100

Chemical Biology and Drug Design

AUGUST 21, 2023

Further, the study detected the effect of SA on cell apoptosis, lipid peroxidation, Fe 2+ level, and ferroptosis-related proteins expression. Finally, the effect of HMGB1 expression on SA in H/R stimulation was studied. Such effects of SA on H/R-induced cells were rescued by HMGB1 overexpression.

Protein Expression 100

Protein Expression Treatment Research 100

Chemical Biology and Drug Design

FEBRUARY 15, 2024

However, the DE disease pathogenesis remains unclear, thereby affecting its clinical treatment. RT-qPCR and western blotting were used to test the mRNA and protein expression levels of IL-17 and retinoid-related orphan receptor-γt (RORγt). PGE2 was highly expressed in the DE mouse model.

Disease 100

Disease Protein Expression Regulations Treatment 100

Chemical Biology and Drug Design

SEPTEMBER 21, 2023

Concretely, CPT-11 induced delayed diarrhea rat model and intestinal epithelial cell (IEC)-6 cell injury model with Baicalein treatment as needed. Colonic pathological changes were analyzed by hematoxylin–eosin staining, and inflammatory factor expressions in serum were determined by enzyme-linked immunosorbent assay.

Protein Expression 100

Protein Expression Treatment Research 100

Chemical Biology and Drug Design

DECEMBER 6, 2023

However, the pharmacodynamic mechanism and molecular target of SP-FC in the treatment of HS are still unclear. Therefore, this study is intended to explore the mechanism and target of SP-FC in the treatment of HS through network pharmacology combined with in vitro cell and molecular biology experiments.

Molecular Biology 100

Molecular Biology Protein Expression Treatment Regulations 100

Chemical Biology and Drug Design

MARCH 4, 2024

Abstract Anlotinib is used for the treatment of advanced non-small cell lung cancer; however, the emergence of drug resistance limits its clinical application. The expression of miR-181a-3p was inhibited; however, SHQ1 expression was increased by β-sitosterol treatment of A549/anlotinib cells.

Protein Expression 100

Protein Expression Regulations Treatment Drugs 100

Chemical Biology and Drug Design

DECEMBER 8, 2023

ELANE knockdown offset CAMP silencing-mediated inhibition of viability and promotion of inflammatory factors and pyroptosis-related protein expression in LPS/ATP/BoNT/A-treated rat DRG neurons. Conclusively, BoNT/A alleviates rat DRG neuron pyroptosis during PHN by upregulating CAMP to inhibit ELANE.

Protein Expression 100

Protein Expression Treatment Research 100

Drug Target Review

APRIL 14, 2025

With many healthcare systems prioritising cost-effectiveness, there is limited demand for novel treatments, even though they are crucial to combatting antibiotic resistance. Traditional biologics often involve recombinant protein expression in mammalian cells or microbes like E.

Therapies 52

Therapies Marketing Drug Development Treatment 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

OCTOBER 6, 2023

This interview explores how CoRegen’s innovative techniques are not only transforming cancer treatment but also hold promise for a wide range of medical applications, all while minimising the side effects often associated with traditional therapies.

Small Molecule 111

Small Molecule Engineering Protein Expression Therapies 111

The Pharma Data

NOVEMBER 26, 2020

(NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

SEPTEMBER 10, 2020

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study. 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Drug Target Review

FEBRUARY 19, 2024

Knowing that the work I was doing could potentially provide a new or improved treatment options helped me to persevere. I did my PhD project on elucidating the role of the p53 protein that is relevant in many cancers. There are many failures and setbacks in drug discovery, and you need a lot of resilience to keep going.

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

DrugBank

JULY 24, 2024

For example, PROTACs targeting STAT3, a protein crucial for tumor growth, have shown promise where conventional therapies have failed. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Broad Institute

SEPTEMBER 5, 2024

In recent years, increasingly sensitive mass spectrometers have paved the way for enormous progress: scientists are now able to detect and analyze nearly all proteins expressed in a sample, including ones present only in miniscule amounts. It's a matter of how much of that protein is present relative to its environment.

Disease 85

Disease Protein Expression Engineering Treatment 85

Broad Institute

AUGUST 24, 2022

Louis have identified biological markers in triple negative breast cancer (TNBC) that are associated with resistance to chemotherapy treatment. It is imperative that we develop approaches to predict response so that only effective treatments are given. 33, was associated with resistance to chemotherapy treatment.

DNA 52

DNA Treatment Protein Expression Protein Production 52

The Pharma Data

MAY 2, 2022

The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC). View the full release here: [link].

Licensing 52

Licensing Licensing Research Protein Expression 52

PPD

OCTOBER 12, 2023

These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

JUNE 7, 2023

1,2 While first-line treatment with immune checkpoint inhibitors with or without chemotherapy has improved outcomes for patients with NSCLC without AGAs, like EGFR or ALK, most patients eventually experience disease progression. 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. Source link: [link]

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

APRIL 8, 2021

today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

The Pharma Data

DECEMBER 8, 2020

Li stated, “One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. co-founder, president and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence. . Pear Therapeutics.

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

AUGUST 16, 2021

The vaccine candidate, presently at a preclinical development stage, is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). CureVac had its initial public offering on the New York Nasdaq in August 2020.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

SEPTEMBER 8, 2020

Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 11-13 September 2020. “We

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

The Pharma Data

SEPTEMBER 2, 2020

New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence. Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations.

Clinical Trials 52

Clinical Trials Treatment Disease Therapies 52

The Pharma Data

APRIL 26, 2022

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Target Review

MAY 4, 2023

A cure for sickle cell anaemia A recent scientific breakthrough in the treatment of sickle cell anaemia —a genetic disorder marked by episodes of intense pain—illustrates how combining GWAS with cutting-edge molecular tools like gene editing can identify causal variants and lead to innovative therapies.

Disease 52

Disease Small Molecule Protein Expression Research 52

The Anticancer Fund

SEPTEMBER 29, 2021

Top story A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 Published in Neuro-Oncology Advances The CUSP9v3 combines nine repurposed non-cancer drugs with metronomic temozolomide for patients with recurrent glioblastoma.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

The Pharma Data

OCTOBER 28, 2020

NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. The UBE3A antisense transcript targeted by GTX-102 is a viable target for treatment,” stated Scott Stromatt, M.D.,

Protein Expression 40

Protein Expression Therapies Treatment Disease 40